Buspirone augmentation of antidepressant therapy

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Major depressive disorder (MDD) is a prevalent mental health condition.
• A significant portion of patients with MDD do not respond adequately to initial antidepressant monotherapy.
• Treatment resistance in depression necessitates exploring augmentation strategies.

Purpose of the Study:

• To evaluate the efficacy of buspirone as an adjunctive treatment for major depression in patients with inadequate response to standard antidepressants.
• To assess the safety and tolerability of buspirone augmentation therapy.

Main Methods:

• A study involving 30 outpatients diagnosed with major depression (DSM-III-R/DSM-IV) who failed adequate antidepressant trials.
• Participants received buspirone (20-30 mg/day) for 4-5 weeks in addition to their existing antidepressant medication.
• Response was assessed based on remission of depressive symptomatology and changes in the Clinical Global Impressions Scale.

Main Results:

• Adjunctive buspirone therapy resulted in complete or partial remission in 59% of patients on selective serotonin reuptake inhibitors (SSRIs) and 63% on clomipramine.
• Responders showed a significant mean reduction of 64% on the Clinical Global Impressions Scale (p < 0.0001).
• Combination therapy was well-tolerated with no serious adverse events observed. Long-term follow-up showed sustained remission in 79% of initial responders.

Conclusions:

• Buspirone augmentation is a promising strategy for enhancing treatment response in patients with major depression resistant to standard antidepressant therapies.
• The combination of buspirone with SSRIs or clomipramine demonstrates significant efficacy and a favorable safety profile.
• Further research into buspirone augmentation for treatment-resistant depression is warranted.